Understanding Brain Age Multiple Sclerosis and Accelerated Neurodegeneration

Multiple sclerosis is a chronic autoimmune disorder causing progressive demyelination and structural neurodegeneration throughout the central nervous system. Evaluating brain age multiple sclerosis metrics provides clinicians with vital structural insights into individual disease progression beyond traditional radiological markers. Specifically, researchers calculate the brain-predicted age difference by subtracting chronological age from predicted biological brain age using advanced machine learning models on magnetic resonance imaging scans. Consequently, a higher positive difference signifies accelerated biological brain aging and ongoing tissue loss.

Historically, identifying the specific impact of modifiable disease-modifying factors on brain aging remained challenging because chronological age inherently confounded neuroimaging metrics. However, assessing these structural changes in same-age patient cohorts eliminates chronological age as a confounding variable. Recent clinical investigations demonstrate that lifestyle choices and systemic health factors directly alter biological brain aging trajectories in individuals with multiple sclerosis. Therefore, understanding how accelerated brain aging mediates clinical disability and cognitive impairment allows neurologists to develop targeted management strategies. Furthermore, addressing modifiable risk factors alongside standard disease-modifying therapies may preserve neurological function over time.

Methodology: Evaluating Brain-PAD in Same-Age Cohorts

To assess the interplay between brain aging, clinical disability, and lifestyle factors, researchers conducted a comprehensive cross-sectional study utilizing a standardized cohort. The study evaluated two hundred forty-two individuals with multiple sclerosis alongside one hundred seventeen age-matched healthy controls. All participants shared a narrow chronological age range, effectively eliminating calendar age as a potential confounding factor during statistical modeling.

Investigators acquired three-dimensional T1-weighted brain MRI scans to compute predicted brain age via validated machine learning algorithms, specifically the brainageR processing tool. Subsequently, they calculated brain-predicted age difference scores to quantify relative neurostructural acceleration. Additionally, clinicians systematically quantified physical disability using standardized clinical metrics, including the Expanded Disability Status Scale, timed twenty-five-foot walk test, and nine-hole peg test. Cognitive function was evaluated through the Minimal Assessment of Cognitive Function in MS battery, converting raw scores into standardized z-scores. Meanwhile, multivariable regression models evaluated various disease-modifying factors—such as lifetime tobacco exposure, alcohol intake, physical activity levels, diet, educational attainment, and early-adulthood body mass index—adjusting for sex.

Impact of Lifestyle Factors on Brain-Predicted Age Difference

The findings revealed striking associations between modifiable lifestyle behaviors and accelerated biological brain aging among participants. Specifically, lifetime smoking history was strongly associated with a significantly higher brain-predicted age difference score. Similarly, higher levels of regular alcohol consumption and elevated body mass index at age eighteen independently predicted advanced biological brain aging relative to chronological age. These findings suggest that early systemic metabolic stress and toxic exposures exacerbate ongoing neurodegenerative cascades in multiple sclerosis.

Conversely, engaging in regular physical activity demonstrated a protective association, correlating directly with lower brain-predicted age difference values. Thus, routine exercise appears to exert a potential neuroprotective effect that preserves structural brain integrity against disease-related atrophy. Surprisingly, factors such as dietary quality, leisure engagement, and educational attainment did not exhibit statistically significant direct effects on brain aging scores in this cohort. Overall, these results highlight that common lifestyle risk factors actively accelerate structural neurodegeneration in patients. Consequently, clinical interventions targeting smoking cessation, weight management, and physical exercise remain vital therapeutic components.

Mediation Dynamics: How Brain-PAD Drives Disability and Cognitive Decline

A key focus of this research involved performing formal mediation analyses to determine whether accelerated brain aging directly connects lifestyle factors to physical disability and cognitive decline. Statistical mediation models confirmed that brain-predicted age difference acts as a primary mediator through which modifiable factors influence clinical outcomes. Specifically, tobacco smoking and alcohol intake exerted significant indirect effects on disability scores, including the Expanded Disability Status Scale and manual dexterity.

Furthermore, mediation analyses demonstrated that accelerated brain aging accounted for a substantial portion of the negative impact of smoking on cognitive performance, particularly in processing speed and memory function. Consequently, these adverse lifestyle factors actively drive structural brain loss, which directly translates into measurable clinical disability. In contrast, physical activity indirectly supported better cognitive scores and physical performance by mitigating biological brain age elevation. Therefore, brain aging functions as a critical intermediary pathological link between external disease-modifying factors and patient disability. Understanding these mediation pathways reinforces the necessity of early risk factor identification in routine clinical neurology practice.

Clinical Implications for Neurological Care and Modifiable Risk Factors

These structural and clinical findings offer transformative implications for daily neurological care and long-term patient management. Traditionally, multiple sclerosis management focused predominantly on suppressing neuroinflammation and relapse activity through pharmaceutical disease-modifying therapies. However, these insights emphasize that controlling neuroinflammation alone may not fully arrest underlying neurodegeneration if modifiable systemic lifestyle risk factors remain unaddressed. Neurologists must incorporate comprehensive lifestyle counseling into routine clinical practice, prioritizing smoking cessation and physical activity promotion.

Additionally, managing metabolic health during adolescence and early adulthood, such as maintaining a healthy body mass index, plays a crucial role in preserving long-term brain health. Clinicians should educate patients that daily habits directly influence structural brain preservation and functional reserve. Moreover, incorporating advanced MRI-derived neuroimaging metrics like brain-predicted age difference into clinical evaluation could enhance risk stratification. Identifying patients with accelerated brain aging allows clinicians to tailor intensive monitoring and multidisciplinary lifestyle interventions promptly. Ultimately, combining robust anti-inflammatory therapies with lifestyle modification provides a comprehensive, dual-pronged strategy to preserve brain structure.

Future Directions in Neuroimaging Biomarkers and Intervention

As neuroimaging technology advances, integrating biological brain age estimates into clinical trials and observational studies will refine personalized medicine approaches in neurology. Future longitudinal studies should investigate whether targeted lifestyle interventions, such as structured exercise regimens and dietary modifications, can reverse or slow accelerated brain aging over extended periods. Furthermore, researchers must explore how specific disease-modifying therapies interact with lifestyle factors to alter brain aging trajectories across different disease phenotypes.

In addition, validating automated brain age algorithms in diverse patient populations will broaden their clinical utility and accessibility. Developing standardized, automated tools for routine MRI interpretation will enable clinicians to monitor neurodegeneration seamlessly in outpatient settings. Ultimately, establishing brain aging as a validated surrogate biomarker will accelerate the evaluation of novel neuroprotective therapeutic strategies. By combining non-pharmacological risk reduction with advanced disease-modifying agents, healthcare providers can better preserve cognitive capacity, reduce physical disability, and enhance overall quality of life for individuals living with multiple sclerosis.

Frequently Asked Questions

What is brain-predicted age difference in multiple sclerosis?

Brain-predicted age difference, or brain-PAD, measures the gap between a patient's chronological age and structural brain age calculated from MRI scans using machine learning. In multiple sclerosis, a positive brain-PAD reflects accelerated neurodegeneration, indicating that the patient's brain appears structurally older than their actual calendar age.

How do lifestyle factors affect brain aging and disability in MS patients?

Modifiable factors like tobacco smoking, alcohol consumption, and high adolescent BMI accelerate biological brain aging. Mediation analysis shows that these factors increase brain-PAD, directly contributing to greater physical disability and cognitive decline. Conversely, regular physical activity helps reduce brain-PAD, offering neuroprotective benefits that preserve functional independence.

Can lifestyle modifications slow down brain aging in multiple sclerosis?

Yes, evidence indicates that adopting healthy lifestyle modifications can slow accelerated brain aging. Engaging in routine physical activity, quitting smoking, moderating alcohol intake, and managing adolescent body weight reduce biological brain age progression, thereby helping preserve long-term cognitive function and physical mobility alongside standard disease-modifying therapies.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Bos L, Wink AM, Cole JH, Pontillo G, Moraal B, Killestein J, de Jong BA, Uitdehaag BMJ, Barkhof F, Schoonheim MM, Jasperse B, Strijbis EMM. Mediation Analysis Between Brain Age, Disease-Modifying Factors, and Disability and Cognitive Performance in Multiple Sclerosis. Neurology. 2026 Jul 14. doi: 10.1212/WNL.0000000000218161. PMID: 42308438.